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Abstract 
This study assessed the correlation between the areas of the Interviewer Severity Rating 
(ISR) and the areas of the Composite Scores (CS) of the EuropAsi. It evaluated the 
predictive validity of both types of scoring with regard to completion of treatment. For 
this purpose, 252 patients were interviewed using the EuropAsi. 38.9% of patients 
discontinued treatment. Results indicated a high correlation between various areas of the 
ISR and the CS, except the legal and family-others scales. Regarding predictive results, 
patients with a score greater than 3 in the ISR family area were more likely to quit the 
programme compared to patients with a score lower than 3. Patients with a CS score 
that was greater than 0.34 in the alcohol-use area were more likely to drop-out of 
treatment. When both ISR and CS scores were included in the prediction model, the ISR 
family area was a better predictor.  
 
 
Keywords: EuropAsi; Composite Scores; Interviewer Severity Rating; drop-out rates; 
treatment; drug dependence 
 
 
López-Goñi, J.J., Fernández-Montalvo, J. y Arteaga, A. (2012). Predictive validity 
of the EuropAsi: Clinical diagnosis or composite scoring? Journal of Substance 
Abuse Treatment, 42, 392-399. http://dx.doi.org/10.1016/j.jsat.2011.09.011 
3 
1. Introduction 
Drug addiction is a multi-dimensional problem that affects all facets of life for 
people who suffer from it (Ana et al., 2008; Carroll & Rounsaville, 2002). However, 
there is significant variance in the manner in which each patient is affected by addiction. 
When the specific characteristics of each patient are analysed more thoroughly than 
during group assessments, different treatment needs can be observed (Fernández-
Montalvo, López-Goñi, Illescas, Landa, & Lorea, 2007; Grella, Hser, Joshi, & Douglas 
Anglin, 1999; López-Goñi, Fernández-Montalvo, Illescas, Landa, & Lorea, 2008b; 
López-Goñi et al., 2010; Ravndal, Vaglum, & Lauritzen, 2005; Sayre et al., 2002). 
Various measurements have been developed to assess patient condition at both 
the beginning of and during treatment (Carroll & Rounsaville, 2002; Iraurgi & 
González-Saiz, 2002). One of the most commonly used measurements is the European 
version of the Addiction Severity Index (ASI) (McLellan, Luborsky, Woody, & 
O´Brien, 1980), to be referred to as the EuropAsi (Kokkevi & Hartgers, 1995). The 
Spanish version was developed by Bobes, González, Sáiz and Bousoño (1996). This 
measurement involves an interview that is often used from a clinical perspective (e.g., 
for screening, clinical evaluation, and result evaluation) and from an institutional 
perspective (e.g., to evaluate programme results, compare treatment mechanisms, 
compare subpopulations of patients, and compare different contexts of treatment) 
(González-Saiz et al., 2002; Mäkelä, 2004). 
This interview assesses the patient's need for treatment in seven different areas: 
a) general medical condition; b) professional and financial situation; c) alcohol 
consumption; d) other drug consumption; e) legal problems; f) family and social 
relations; and g) psychological condition. After concluding the interview, the 
intervention team assesses the patient's need for treatment in each of these areas. The 
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Interviewer Severity Rating (ISR) can be used for this assessment. This rating is 
calculated based on a series of critical items in each of the areas so as to consider the 
patient's own self-evaluation and the interviewer's judgement, and yields a score ranging 
from 0 (no problem) to 9 (extreme problems). A higher score indicates a more severe 
addiction, with severity defined as the need for treatment if there is no current treatment 
in process or as the implementation of additional treatment if the patient is already 
receiving some type of intervention. The highly subjective nature of this assessment, as 
it is based on the treatment team's opinion, has been criticised (Sánchez-Hervás, 
Secades-Villa, Gómez, Romaguera, & García-Rodríguez, 2009), so a 2-step assessment 
method was developed to increase the reliability of the ISR (Bobes et al., 2008).  
Various studies have examined the psychometric properties of the ASI 
(McLellan et al., 1985; Mäkelä, 2004), the EuropAsi (Mäkelä, 2004), and the Spanish 
version of the ASI (González-Saiz, et al., 2002). Generally, the results of the studies 
indicate some adequate psychometric properties. However, the ISR is generally not 
recommended for measuring results in the research sector or in programme evaluation 
studies. Composite Scores (CSs) should be used in the place of the ISR (Bobes, et al., 
2008; Kokkevi & Hartgers, 1995).  
The CS was developed to obtain ratings that would facilitate the comparison of 
results from different treatment programmes. These ratings are arithmetically developed 
indicators based on information provided by the patients about their activities over the 
past 30 days, and about their perceived need for help (Koeter & Hartgers, 1997; 
McLellan, et al., 1985). The European version of the ASI is composed by 9 CS scales. 
This is because there are two scales (employment status and family situation), each of 
which are divided in two subscales: economic situation and employment satisfaction; 
and family relationships and relationships with others respectively. The ratings range 
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from 0.00 to 1.00, with higher values indicating greater severity of each area. It is 
important to note that the different subscales are not standardised, meaning that similar 
values between the different areas do not indicate similar severity. Typically, there is a 
high level of internal consistency for alcohol consumption, medical areas, and 
psychiatric areas. There is a low level of consistency for the other areas (Mäkelä, 2004). 
Romelsjo (2004) found a low correlation between the severity of the addiction and the 
CS. 
Nevertheless, there is still some support for the use of the ISR in the research 
sector. Mäkelä (2004) argues that the usefulness of CSs has been overestimated. In 
particular, there are 3 major problems with CSs (Melberg, 2004): 1) The scores do not 
provide a clear profile of each patient's global situation in that the ratings between the 
different areas cannot be compared for a single case. The ISR provides comparable 
scores. 2) It is difficult to interpret the scope of changes in the scores. 3) The scores are 
based on events from the previous 30 days, thereby ignoring elements of the patient's 
life that can condition his/her evolution. These elements are typically taken into account 
by a general practitioner when he/she plans future treatment. However, the 
recommendation to avoid the use of the ISR in the research sector has been 
overgeneralised to apply to any use, including evaluating patients' results or programme 
results. In contrast, it has been argued that ISRs are more useful than CSs in some 
specific contexts, for example in therapeutic communities (Soyez, De Leon, Broekaert, 
& Rosseel, 2006). It is also possible to use both ISRs and CS as measures of severity of 
drug addiction (Davis et al., 2002).  
In fact, when the Spanish version of the ISR was used, results were generally 
positive for both the involved treatment teams and with regard to research on drug 
addiction treatment (Casares-Lopez et al., 2010; Fernández-Montalvo, Lorea, López-
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Goñi, & Landa, 2008; Fernández-Montalvo & López-Goñi, 2010; Graña, Muñoz, & 
Navas, 2009; Landa, Fernández-Montalvo, López-Goñi, & Lorea, 2006; López-Goñi, 
Fernández-Montalvo, Illescas, Landa, & Lorea, 2008a). From a clinical perspective, this 
finding confirms that a clinical diagnosis is necessary to determine a psychopathological 
diagnosis (Fernández-Montalvo & Echeburúa, 2006). A good diagnosis is also 
imperative for guiding treatment in an appropriate manner. Internationally, there are at 
least two studies that provide interesting results for the clinical sector that have made 
use of both the ISR and CSs simultaneously (Soyez, et al., 2006; Walton-Moss & 
McCaul, 2006).  
Research has focused on analysing the relationship between ISRs and CSs. In 
the ASI, some moderate correlations have been found between the two types of scoring 
(Alterman, Brown, Zaballero, & McKay, 1994). With regard to the EuropAsi, the 
German version has shown high correlations between ISRs and CSs, as well as good 
inter-rater reliability (Scheurich et al., 2000; Weiler, Vogt, & Küfner, 2000). Results 
have also been obtained for the Hungarian version that shows statistically significant 
correlations of a high magnitude between the 2 types of scoring (Gerevich, Baskai, Ko, 
& Rozsa, 2005). In contrast, the Norwegian version specified modifications to improve 
construct validity and reliability (Lauritzen & Ravndal, 2004).  
A Spanish study analysed the relationship between the two types of scoring 
(Sánchez-Hervás, et al., 2009). The authors concluded that it was not advisable in the 
research sector to use the ISR to measure results. This study compared the values within 
the different CS sections. However, as mentioned previously, the CS scores obtained are 
not comparable across sections. Consequently, the conclusions obtained in this study 
must be considered with caution. No other Spanish study has been conducted to directly 
compare the correlation between the two types of scoring.  
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The current study has two goals: First, from a psychometric perspective, it aims 
to assess the relationship between the different areas of the ISR, and the corresponding 
areas of the CS. Second, from a clinical perspective, it will compare the predictive 
validity of both types of scoring with regard to treatment drop-out rates. It should be 
kept in mind that the primary use of the EuropAsi is to personalise treatment for each 
patient. A good indicator of a successful match between patient and treatment is 
treatment completion. Although several studies have assessed the predictive usefulness 
of the ISR (Fernández-Montalvo & López-Goñi, 2010) or of the CS (Casares-Lopez, et 
al., 2010; López-Goñi et al., 2011), this will be the first published study to compare the 
predictive validity of the two types of ratings.  
2. Method 
The protocol for this study was approved by the ethics committees of the Public 
University of Navarra and of the Fundación Proyecto Hombre de Navarra.  
2.1. Subjects 
The sample consists of 252 consecutive addicted patients who came to the 
Fundación Proyecto Hombre de Navarra (Spain) to obtain outpatient treatment between 
October 2008 and July 2010. The treatment is individually based and aimed at 
withdrawal from drug use.  
The admission criteria for subjects in this study were that they must: a) fulfil the 
diagnostic criteria for substance addiction disorder according to the DSM-IV-TR 
(American Psychiatric Association, 2000); b) be between the ages of 18 and 65 years; c) 
be enrolled in the treatment programme; and d) sign a consent form to participate. 
The patients' average age was 37.6 years (SD = 9.5), with 203 (80.5%) men and 
49 (19.5%) women. The rate of patients who dropped out of the intervention 
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programme was 38.9% of the sample (N = 98). The main characteristics of the sample 
are described in table 1.  
Insert Table 1 here 
2.2. Evaluation 
Subjects were evaluated with the EuropAsi (Kokkevi & Hartgers, 1995). As 
previously discussed, the EuropAsi is the European version of the Addiction Severity 
Index (ASI) (McLellan, et al., 1980). The Spanish version was developed by Bobes, 
González, Sáiz and Bousoño (1996). For the current study, both the ISR and CS were 
used. 
2.3. Procedure 
After selecting the sample according to the admission criteria, the subjects were 
interviewed by clinical psychologists who had seven or more years of experience in 
treating addictions and in applying the EuropAsi. Following interviews, the ISR was 
calculated according to the 2-step methodology suggested by Bobes et al. (2008). 
Moreover, each subject's CS was calculated by a computerised system, according to the 
method developed by Koeter & Hartgers (1997). This method has been used in different 
studies (De Wilde et al., 2004; Haasen et al., 2009; McSweeney, Stevens, Hunt, & 
Turnbull, 2007). Detailed tracking of each subject's progress was also maintained. The 
goal of this study was to assess whether the subject completed the treatment by 
obtaining a therapeutic discharge or whether the subject dropped out (i.e., abandoned 
the treatment before obtaining a therapeutic discharge) of treatment before the 
conclusion of the programme.  
2.4. Data Analysis 
Descriptive analyses were conducted for all variables. To assess the level of 
relationship between the ISR and the CS, a Pearson's correlation index was used. For 
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bivariate analyses, χ2 tests or t tests were used depending on the nature of the variables 
being analysed, with a probability of less than 0.05 considered significant. Regarding 
multivariate analysis, first a logistic regression (step by step forward model) was carried 
out in order to know if the two scores (ISR and CS) were additive. Second, a CHAID 
analysis was applied as a post-hoc test to explain significant OLS. Both analyses used 
the following models: 1) ISR discriminating ability; 2) CS discriminating ability; and 3) 
discriminating ability of ISR and CS together. All statistic analyses were conducted 
with the SPSS programme (version 15.0).  
3. Results 
3.1. Scoring in the EuropAsi 
Table 2 presents the results obtained from the EuropAsi. For the ISR, the highest 
subscale refers to alcohol consumption and the lowest subscale refers to legal problems. 
For the CS, the scoring oscillated between 0.11 and 0.38. However, it is important to 
note that in the CS, the various areas cannot be compared to one another.  
Insert Table 2 here 
As for the progress of subjects during treatment, a total of 98 subjects (38.9%) 
dropped out of the programme prior to completion. Regarding the ISRs, subjects who 
dropped out of treatment showed more severity in their alcohol consumption, in family 
and/or social issues, and in psychiatric issues at the time of enrolment. However, those 
who completed the treatment showed a higher severity in drug consumption.  
When comparing the two groups in the CS, subjects who dropped out of 
treatment had more problems related to professional dissatisfaction, alcohol abuse, and 
family conflicts.  
3.2. Correlation between the ISR and CS 
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Table 3 presents the correlations between the ISR and CS, and reveals that apart 
from the legal area, all ISRs are correlated to their corresponding areas in CSs. These 
significant correlations vary between 0.728 on the drug area and 0.314 on the relations-
others area.  
Insert Table 3 here 
3.3. Prediction of Therapeutic Results 
The results of the analyses carried out in order to establish the discriminating 
ability of the different models are presented in Table 4. Regarding logistic regression 
analysis, the higher relative predictive ability came from the model 3 (ISR + CS). 
Insert Table 4 here 
The results of the CHAID analysis with the three assessed models (ISR, CS or 
ISR + CS) showed two statistically significant variables: the family area of the ISR and 
the alcohol area of the CS. When ISRs were included as independent variables (model 
1), a rating higher than 3 on the family area suggested that the probability that a subject 
would drop out of treatment was doubled When CSs were included as independent 
variables (model 2), the dropout probability increased if the rating for alcohol 
consumption was higher than 0.34. When both ISRs and CSs were incorporated (model 
3), the variable that explained the difference between dropouts and therapeutic 
successes was the family scale of the ISR.  
4. Discussion 
This study provides evidence that the CSs and the ISRs produce unique and 
additive information about patients’ condition. The ISRs provide useful information that 
must be considered, because the judgments based on the CS alone may ignore clinically 
important information either in treatment planning, or in research. 
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Moreover, this study shows the usefulness of the EuropAsi when determining 
whether patients will successfully complete drug addiction treatment. As is evident 
from previous studies (Fernández-Montalvo & López-Goñi, 2010; López-Goñi, et al., 
2010), patients who drop out of treatment generally have higher ratings on the different 
areas of the EuropAsi. It is logical to conclude that patients who have more difficulty, 
which both the ISR and CS are sensitive to, drop out of treatment at a larger proportion 
than patients who do experience difficulty. Therefore, it is imperative to integrate 
improvements in the treatment of addiction so that patients, both with and without 
difficulties, will complete the programmes.  
In this study, patients with major problems on the ISRs in the areas of alcohol 
consumption, family/social relations, and psychiatry were more likely to drop out of 
treatment. In contrast, patients who had more severe CS ratings on alcohol consumption 
across the previous 30 days, more professional dissatisfaction, and more family/social 
issues were also more likely to dropout. Both perspectives are compatible and provide 
directions for areas to implement improvements in the assessed treatment programme. 
Across both rating types, the family area of the ISR is revealed as the breaking point in 
which the treatment dropout probability is doubled (family > 3, 51.4% vs. family < 3, 
25.4%). The fewer the family issues, the higher the probability is that a patient will 
complete the treatment.  
This study also provides evidence regarding the high correlation (with values 
higher than 0.53) in five of the seven assessed areas in the ISRs and CSs for an 
outpatient drug addiction treatment programme in Spain. This finding supports similar 
results from other studies (Alterman, et al., 1994; Mäkelä, 2004; Scheurich, et al., 
2000). The low correlation (0.367) between the ISR family area and the CS others area 
indicates that an independent assessment of family relations and social relations (e.g., 
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friends, colleagues, and neighbours) should be included in the ISR. In a Spanish 
context, it is common to treat patients with strong social support and weak family 
support, or vice versa. Future research should continue to focus on investigating the 
relationship between these areas. Anyway, the only area not correlated with another was 
the legal area (0.014). Given that the correlations between areas that do not match are 
low, this may provide support for independence between the areas assessed by the 
EuropAsi (McLellan, et al., 1985). 
With regard to the predictive value of the ISR and the CS towards patient 
treatment progress, it appears that both types of scoring can provide relevant 
information and valuable feedback to the treatment team that supports improvement of 
specific actions. Both ISRs and CSs have strengths and weaknesses given that they 
examine different aspects of the same phenomenon. Accordingly, various indices based 
on distinct items of the ASI or the EuropAsi have been developed (Sizoo et al., 2010; 
Soyez, et al., 2006), which paves the way for new uses for these measurements.  
The results of this study also provide support for the usefulness of the ISR both 
in the clinical and in the research sector, as has been found in previous studies (Davis, et 
al., 2002). It is contradictory that using ratings based on the addicted patients' answers 
(CS) is recommended, whereas other ratings (ISR) based on the clinical impressions of 
those who will be assigned to treat addicted patients are relegated. Both the patient and 
the practitioner are essential elements of treatment, and each perspective is important. In 
this respect, there can be various differences between this study and other studies that 
have not found a positive relationship between ISRs and CSs (Sánchez-Hervás, et al., 
2009). One of these differences is methodological. The validity criterion used in this 
study was whether the patients completed treatment. Another difference could be 
associated with the experience and training of the treatment team (with a large amount 
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of experience evident in the team for this study). A third difference could be due to the 
manner in which the ISRs were assessed (although the 2-step way is specified in the 
manual, some teams only follow the interviewer's criterion). Factors such as these can 
negatively affect the reliability of the ISR.  
This study has various limitations that must be taken into consideration. The first 
limitation is methods of calculating the ISR and CS. The ISR’s rating was based on the 
interviewer's clinical opinion, which can result in a self-fulfilling prophecy for the 
patient. Several authors note that the most difficult patients can receive a less intense 
treatment than they should, often because it is more likely that their appointments are 
postponed or cancelled (Hall, Popkin, Devaul, & Stickney, 1977). The CS rating was 
based on statements made by patients regarding their own behaviour over the previous 
30 days. It is relatively frequent to find patients who either try to simulate more severity 
or try to dissimulate the severity of their behaviour, both of which affect the validity of 
the CS. Another limitation is related to the sample assessed in this study. Even with a 
relatively large sample of patients, this sample is primarily composed of patients who 
ask to be treated for consumption of different substances, which may not be 
representation of the general addicted population. Moreover, only 20% of the sample 
was women. For this reason, some caution must be taken regarding the generalisation of 
the results obtained. Lastly, the use of patients’ successful completion of treatment as 
the variable being analysed with regard to the predictive validity of the ISRs and CSs 
also limits the generalisation of these results. Future research should assess the 
predictive validity of these measurements regarding potential relapses after treatment 
completion. Overall, the main objective of the treatment programmes should be patient 
recovery, and not just treatment completion.  
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In conclusion, a sixth version of the ASI has recently been introduced in which 
ISRs were eliminated (Mesa et al., 2010). If similar results to this study are presented in 
the future, it may be possible to reconsider this elimination. The ISRs could constitute 
another tool for assessment these patients. A solid and accurate assessment criterion 
could help clinicians to design tailored programs for this kind of patients. 
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Table 1. Characteristics of the sample 
 
 All N = 252 
Therapeutic discharge 
(n = 154) 
Drop-out 
(n = 98) 
 
 Mean (SD) Mean (SD) Mean (SD) t 
        
Mean age  37.6 (9.5) 36.8 9.4 38.7 9.5 1.5 
        
 All (N = 252) 
Therapeutic discharge 
(n = 154) 
Drop-out 
(n = 98) 
 
 N (%) n (%) n (%) X2 
Sex        
Men 203 (80.5%) 126 (81.8%) 77 (78.6%) .4 Women 49 (19.5%) 28 (18.2%) 21 (21.4%) 
        
Marital Status        
Single 122 (48.4%) 71 (46.1%) 51 (52.0%) 
3.6 Married 76 (30.2%) 53 (34.4%) 23 (23.5%) Divorced 50 (19.8%) 28 (18.2%) 22 (22.4%) 
Widower 4 (1.6%) 2 (1.3%) 2 (2.0%) 
        
Education        
None 28 (11.2%) 15 (9.8%) 13 (13.3%) 
1.4 Primary school 135 (53.8%) 81 (52.9%) 54 (55.1%) Secondary school 62 (24.7%) 41 (26.8%) 21 (21.4%) 
University 26 (10.4%) 16 (10.5%) 10 (10.2%) 
        
Employment situation        
Employed 166 (65.9%) 109 (70.8%) 57 (58.2%) 
4.3 Unemployed 68 (27.0%) 35 (22.7%) 33 (33.7%) 
Others (student. retired. etc.) 18 (7.1%) 10 (6.5%) 8 (8.2%) 
        
Substance        
Alcohol 109 (43.3%) 59 (38.3%) 50 (51.0%) 
6.4* Cocaine 125 (49.6%) 80 (51.9%) 45 (45.9%) 
Others (heroin. cannabis…) 18 (7.1%) 15 (9.7%) 3 (3.1%) 
        
Another substance abuse 64 (25.4%) 43 (27.9%) 21 (21.4%) 1.3 
Alcohol 15 (6.0%) 8 (18.6%) 7 (33.3%) 
1.7 Cocaine 28 (11.1%) 14 (32.6%) 6 (28.6%) 
Others 21 (8.3%) 21 (48.8%) 8 (38.1%) 
*p < .05 
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Table 2. Description of the Interviewer Severity Ratings (ISR), Composite 
Scoring (CS) and a comparison between discharge and dropout rates 
  
All 
(N = 252) 
Therapeutic discharge 
(n = 154) 
Drop-out 
(n = 98)  
 
  M (SD) M (SD) M (SD) t df 
EuropASI  Medical 2.0 (1.4) 2.0 (1.4) 2.0 (1.3) .1 250 
ISRs Employment/Support 2.4 (1.7) 2.2 (1.6) 2.6 (1.8) 1.9 185.1 
 Alcohol use 3.9 (2.0) 3.7 (1.9) 4.2 (2.0) 2.2* 250 
 Drug use 3.4 (2.1) 3.6 (2.0) 3.0 (2.2) 2.4* 249 
 Legal 1.8 (1.5) 1.9 (1.5) 1.6 (1.3) 1.4 250 
 Family/Social 3.7 (1.7) 3.3 (1.7) 4.2 (1.6) 4.0** 249 
 Psychiatric 3.2 (1.7) 3.0 (1.7) 3.5 (1.8) 2.0* 250 
EuropASI  Medical .22 (.25) .20 (.25) .25 (.26) 1.3 250 
CS Economic situation .38 (.45) .35 (.44) .43 (.46) 1.4 250 
 Satisfaction .27 (.32) .24 (.30) .32 (.35) 1.9* 250 
 Alcohol .31 (.24) .27 (.21) .38 (.26) 3.6** 250 
 Drug use .13 (.12) .10 (.08) .10 (.09) .2 176.6 
 Legal .11 (.19) .13 (.21) .11 (.21) .4 249 
 Family .27 (.23) .24 (.23) .31 (.23) 2.5* 250 
 Others .15 (.18) .14 (.17) .17 (.20) 1.3 248 
 Psychiatric .21 (.19) .19 (.17) .24 (.21) 1.9 175.1 
*p < .05; **p < .001 
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Table 3. Correlations between the Interviewer’s Severity Ratings and the Composite Scores of the EuropAsi at the beginning of the 
treatment.  
 
 
 Composite Scores 
Interviewer’s Severity Ratings Medical Employment Alcohol Drug use Legal Family Psychiatric 
  Economic Situation Satisfaction    Family Others  
Medical .614** .151* .181** .054 -.060 -.029 .141* .042 .151* 
Employment .232** .530** .636** .019 -.023 .050 .111 .101 .174** 
Alcohol use .162** .317** .084 .552** -.335** .020 .199** .016 .249** 
Drug use -.045 .054 .018 -.216** .728** -.037 .046 .182** .094 
Legal .051 .114 .007 -.057 .143* .014 .002 .098 .113 
Family/Social .140* .313** .147* .111 .048 -.059 .539** .367** .341** 
Psychiatric .196** .237** .177** .143* .004 .075 .174** .298** .671** 
*p < .05; **p < .01  
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Table 4. Multivariable analysis for the ISR, the CS, and the ISR together with the CS (logistic regression and CHAID analysis).   
 
 Logistic Regression (Dep. var = Drop-out) 
 Model 1: (IV) = ISR Model 2: (IV) = CS Model 3: (IV) = ISR + CS 
STEP Var. OR 95% CI Var. OR 95% CI Var. OR 95% CI 
1 Family .740 (.63, .87) Alcohol .13 (.04, .40) CS Alcohol .13*** (.04, .41) 
2 Drugs 1.22 (1.01, 1.39) Family .28 (.05, .47) ISR Family .76** (.65, .90) 
3       ISR Drugs 1.16* (1.01, 1.33) 
4       CS Drugs 0** (.0, .06) 
Final model Drugs 1.22** (1.07, 1.4) Alcohol .15** (.05, .47) CS Alcohol .20** (.06, .66) 
 Family .71*** (.60, .83) Family .28* (.09, .9) ISR Family .71*** (.59, .84) 
 Constant 2.9**  Constant 4.1***  ISR Drugs 1.49*** (1.20, 1.84) 
       CS Drugs .0** (.0, .06) 
       Constant 5.4***  
Full model adj. R2 .126   .097   .204   
 CHAID analysis 
 Therapeutic Discharge = 154 (61.1%); Drop-out = 98 (38.9%) 
 Model 1: (IV) = ISR Model 2: (IV) = CS Model 3: (IV) = ISR + CS 
 
Corrected P value = 0.000 
X2 = 18.080 (gl = 1) 
Corrected P value = 0.008 
X2 = 10.938 (gl = 1) 
Corrected P value = 0.000 
X2 = 18.080 (gl = 1) 
 Family < = 3 Family > 3 Alcohol < = 0.34 Alcohol > 0.34 Family < = 3 Family > 3 
 n (%) n (%) n (%) n (%) n (%) n (%) 
Drop-out 31 (25.4%) 67 (51.5%) 47 (30.7%) 51 (51.5%) 31 (25.4%) 67 (51.5%) 
Therapeutic Discharge 91 (74.6%) 63 (48.5%) 106 (69.3%) 48 (48.5%) 91 (74.6%) 63 (48.5%) 
Total 122 (48.4%) 130 (51.6%) 153 (60.7%) 99 (39.3%) 122 (48.4%) 130 (51.6%) 
IV = Independent Variables; ISR = Interviewer Severity Ratings; CS = Composite Scores 
*p < .05; **p < .01; ***p < .001 
 
